Fujifilm has agreed to acquire to acquire Biogen (Denmark) Manufacturing ApS, a large-scale biologics manufacturing site located in Hillerød near Copenhagen, Denmark (Biogen Hillerød), for about $890m in cash.
Nichi-Iko Pharmaceutical and Sagent Pharmaceuticals, a Nichi-Iko Group Company ("Sagent"), a leader of specialty pharmaceutical products with an emphasis on the injectable market, announced that Sagent has acquired an FDA-approved manufacturing site in Raleigh, North Carolina, from Xellia Pharmaceuticals ("Xellia").
Science and technology firm Danaher has agreed to acquire the biopharma business of GE Life Sciences (GE Biopharma) for a cash purchase price of about $21.4bn.
Neuraxpharm Group, a European specialty pharmaceutical company focused on the treatment of central nervous system disorders (CNS), has announced the acquisition of Farmax, a CNS specialty pharmaceutical company, from SVUS Pharma.
apceth Biopharma, a contract manufacturing organization in the field of cell and gene therapy, announced that Hitachi Chemical Co., Ltd. will enter into an agreement to acquire all shares of apceth Biopharma.
NextPharma, a European pharmaceutical contract development and manufacturing organization (CDMO), has agreed to acquire Santen’s Tampere manufacturing facility and associated operations.
BioNTech, a biotechnology company developing precise and individualized immunotherapies for the treatment of cancer and the prevention of infectious diseases, and MAB Discovery, a unique player in the generation and development of sophisticated and therapeutically relevant monoclonal antibodies (mAbs), have entered into a definitive agreement under which BioNTech will acquire MAB Discovery’s operational antibody generation unit.
Japan-based Takeda Pharmaceutical has completed its previously announced $62bn acquisition of Irish rare disease biotech company Shire.
Eli Lilly and Company (Lilly) has agreed to acquire Connecticut-based biopharmaceutical company Loxo Oncology in an all-cash deal worth $8bn.
Catalent, a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has started a $200m capital investment to expand biologics capacity and capabilities.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.